Answers are grounded in this paper and cite their sources.
// Yanyang Zhang 1, * , Xinguang Yu 1, * , Ling Chen 1 , Zhibin Zhang 1 , Shiyu Feng 1 1 Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China * These authors contributed equally to this work Correspondence to: Shiyu Feng, email: fsy72123@163.com Xinguang Yu, email: xinguang_yu@263.net Keywords: EZH2, glioma, biomarker, prognosis Received: July 20, 2016 Accepted: November 14, 2016 Published: November 21, 2016 ABSTRACT Previous studies have investigated the prognostic value of enhancer of zeste homolog 2 (EZH2) expression in patients with glioma but conclude contradictory results. We aimed to comprehensively evaluate the prognostic role of EZH2 in glioma by meta-analysis. The databases of PubMed, Embase and Web of Science were searched. Hazard ratio (HR) and 95% confidence interval (CI) were combined to assess the association between EZH2 and overall survival (OS) as well as progression-free survival (PFS). Odd ratio (OR) and 95% CI were calculated to investigate the relevance of EZH2 on clinical factors. Six studies with 575 patients were included for meta-analysis. The results showed that EZH2 overexpression was correlated with poor OS ( n = 6, HR = 2.23, 95% CI: 1.56–3.19, p < 0.001) and PFS ( n = 3, HR = 2.23, 95% CI: 1.56–3.19, p < 0.001). Subgroup analysis showed that EZH2 had enhanced prognostic value in Asian patients, for WHO grade I-IV and when using immunohistochemistry (IHC) method. In addition, EZH2 was associated with KPS score < 80. No evidence of publication bias was found in this meta-analysis. In conclusion, the present study showed that EZH2 was a potential prognostic marker for poor OS, PFS and lower KPS score in glioma patients.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: